Cover Image
市場調查報告書

囊狀纖維化症的全球市場

Global Cystic Fibrosis Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 321449
出版日期 內容資訊 英文 126 Pages
訂單完成後即時交付
價格
Back to Top
囊狀纖維化症的全球市場 Global Cystic Fibrosis Market 2015-2019
出版日期: 2014年12月17日 內容資訊: 英文 126 Pages
簡介

囊狀纖維化症,是高加索人兒童常見的遺傳性疾病的一種。發病率因族群而不同,與歐洲和北美的高加索系人種相比,亞洲人和非洲人不常見。全球囊狀纖維化症市場預計2014年∼2019年之間以年複合成長率成長32.50%。

本報告提供全球囊狀纖維化症市場相關調查分析、市場概要、市場區隔考察、地區市場的狀況、推動市場的要素、市場課題、供應商分析等相關彙整。

第1章 摘要整理

第2章 簡稱一覽

第3章 該報告的範圍

  • 市場概要
  • 商品

第4章 產品簡介

第5章 市場調查方法

  • 市場調查的流程
  • 調查方法

第6章 簡介

第6章市場的狀況

  • 市場概要

第7章 疾病概要

  • 疾病的理解
  • 病理生理學
  • 流行病學
  • 診斷
  • 囊狀纖維化症的徵兆
  • 經濟負擔

第8章 市場的狀況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔:各分子

  • 生物
  • 小分子

第10章 市場區隔:藥的各給藥途徑

  • 口服
  • 非口服
  • 局部

第11章 市場區隔:各劑型

  • 固體
  • 液體

第12章 各地區劃分

  • 南北美洲
  • EMEA
  • 亞太地區

第13章 主要國家

  • 美國
  • 英國
  • 法國
  • 加拿大
  • 義大利

第14章 購買標準

第15章 市場成長的促進要素

第16章 推動市場的要素與其影響

第17章 市場課題

第18章 促進要素與課題的影響

第19章 市場趨勢

第20章 趨勢與其影響

第21章 供應商狀況

  • 競爭模式
  • 市場佔有率分析
  • 其他/今後的主要供應商

第22章 主要供應商分析

  • Actavis
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals

第23章 本系列的其他報告

圖表

目錄
Product Code: IRTNTR4842

About Cystic Fibrosis

Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country.

Cystic fibrosis is a chronic disease. The production of a high-salt containing sweat and secretion of abnormal viscous mucus are the major symptoms of cystic fibrosis.

TechNavio's analysts forecast the Global Cystic Fibrosis market to grow at a CAGR of 32.50 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Cystic Fibrosis market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis which includes:

  • Small Molecules
  • Biologics

Further, the market is segmented on based on route of administration and dosage form. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Cystic Fibrosis market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Cystic Fibrosis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA region; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Actavis
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals

Other Prominent Vendors

  • Abbott
  • Anthera Pharmaceuticals
  • Arcturus Therapeutics
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Insmed
  • Pharmaxis
  • PharmaSwiss
  • Genzyme
  • Johnson & Johnson
  • Merck Sharp & Dohme
  • Neovii Biotech
  • Novo Nordisk
  • Proteostasis Therapeutics
  • PTC Therapeutics
  • United Medical
  • Venus Remedies

Market Driver

  • Unmet Needs in the Market
  • For a full, detailed list, view our report

Market Challenge

  • Expensive Treatment
  • For a full, detailed list, view our report

Market Trend

  • Increase in Public Awareness
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Zenpep/ Ultresa/ Ultrase/ Ultrase MT
    • 04.1.2. Colomycin/ Colobreathe
    • 04.1.3. Pulmozyme
    • 04.1.4. Cayston
    • 04.1.5. TOBI/ TOBI Podhaler
    • 04.1.6. Kalydeco

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
  • 07.2. Pathophysiology
  • 07.3. Epidemiology
    • 07.3.1. Global
    • 07.3.2. North America
    • 07.3.3. Europe
    • 07.3.4. Africas
    • 07.3.5. Latin America
    • 07.3.6. Middle East
    • 07.3.7. Asia and Oceania
  • 07.4. Diagnosis
    • 07.4.1. Newborn Screening
    • 07.4.2. Carrier Testing
    • 07.4.3. Antenatal Testing
    • 07.4.4. Other Tests
  • 07.5. Manifestations of Cystic Fibrosis
  • 07.6. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Molecule Type

  • 09.1. Biologics
    • 09.1.1. Enzymes
  • 09.2. Small Molecules
    • 09.2.1. CFTR Modulator
    • 09.2.2. Antibiotics

10. Market Segmentation by Route of Administration

  • 10.1. Oral
  • 10.2. Parenteral
  • 10.3. Topical

11. Market Segmentation by Dosage Form

  • 11.1. Solid
  • 11.2. Liquid

12. Geographical Segmentation

  • 12.1. Cystic Fibrosis Market in the Americas
    • 12.1.1. Cystic Fibrosis Market in the US
    • 12.1.2. Cystic Fibrosis Market in the Latin America
    • 12.1.3. Cystic Fibrosis Market in the Canada
  • 12.2. Cystic Fibrosis Market in the EMEA Region
    • 12.2.1. Market Size and Forecast
  • 12.3. Cystic Fibrosis Market in the APAC Region
    • 12.3.1. Market Size and Forecast

13. Key Leading Countries

  • 13.1. US
  • 13.2. UK
  • 13.3. France
  • 13.4. Canada
  • 13.5. Italy

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

  • 21.1. Competitive Scenario
    • 21.1.1. Key News
    • 21.1.2. Mergers and Acquisitions
  • 21.2. Market Share Analysis 2014
    • 21.2.1. F. Hoffmann-La Roche
    • 21.2.2. Novartis
    • 21.2.3. Vertex Pharmaceuticals
    • 21.2.4. Actavis
    • 21.2.5. Gilead Sciences
  • 21.3. Other and Future Prominent Vendors

22. Key Vendor Analysis

  • 22.1. Actavis
    • 22.1.1. Key Facts
    • 22.1.2. Business Description
    • 22.1.3. Business Segmentation
    • 21.1.4. Revenue by Business Segmentation
    • 22.1.5. Revenue Comparison 2013 and 2014
    • 22.1.6. Sales by Geography
    • 22.1.7. Business Strategy
    • 22.1.8. Key Developments
    • 22.1.9. SWOT Analysis
  • 22.2. F. Hoffmann-La Roche
    • 22.2.1. Key Facts
    • 22.2.2. Business Description
    • 22.2.3. Business Segmentation
    • 22.2.4. Revenue by Business Segmentation
    • 22.2.5. Revenue Comparison 2013 and 2014
    • 22.2.6. Sales by Geography
    • 22.2.7. Business Strategy
    • 22.2.8. Key Developments
    • 22.1.9. SWOT Analysis
  • 22.3. Gilead Sciences
    • 22.3.1. Key Facts
    • 22.3.2. Business Description
    • 22.3.3. Business Segmentation
    • 22.3.4. Revenue by Business Segmentation
    • 22.3.5. Revenue Comparison 2013 and 2014
    • 22.3.6. Sales by Geography
    • 22.3.7. Business Strategy
    • 22.3.8. Key Developments
    • 22.3.9. SWOT Analysis
  • 22.4. Novartis
    • 22.4.1. Key Facts
    • 22.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 22.4.4. Revenue by Business Segmentation
    • 22.4.5. Revenue Comparison 2013 and 2014
    • 22.4.6. Sales by Geography
    • 22.4.7. Business Strategy
    • 22.4.8. Key Developments
    • 22.4.9. SWOT Analysis
  • 22.5. Vertex Pharmaceuticals
    • 22.5.1. Key Facts
    • 22.5.2. Business Description
    • 22.5.3. Business Segmentation
    • 22.5.4. Revenue by Business Segmentation
    • 22.5.5. Revenue Comparison 2013 and 2014
    • 22.5.6. Sales by Geography
    • 22.5.7. Business Strategy
    • 22.5.8. Key Developments
    • 22.5.9. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot Of Cystic Fibrosis Disease
  • Exhibit 3: Defects Caused by CFTR Mutation
  • Exhibit 4: Epidemiology of Cystic Fibrosis in the World 2012
  • Exhibit 5: Prevalence of Cystic Fibrosis by Country 2014
  • Exhibit 6: Prevalence Number of Cystic Fibrosis by Country 2014
  • Exhibit 7: Snapshot of US Prevalence of Cystic Fibrosis 2014
  • Exhibit 8: Forecast of Cystic Fibrosis Prevalence in US 2014-2019
  • Exhibit 9: Epidemiology Based on the Education Level in US, 2011
  • Exhibit 10: Epidemiology based on the Marital Status in US, 2011
  • Exhibit 11: Epidemiology based on the Employment Status in US, 2011
  • Exhibit 12: Forecast of Cystic Fibrosis Prevalence in Canada 2014-2019
  • Exhibit 13: Forecast of Cystic Fibrosis Prevalence in the UK 2014-2019
  • Exhibit 14: Age Distribution at Death for Cystic Fibrosis Patients in UK, 2013
  • Exhibit 15: Age Distribution by Gender for Cystic Fibrosis Patients in the UK, 2013
  • Exhibit 16: Age Distribution by Sex for Cystic Fibrosis Patients in the UK, 2013
  • Exhibit 17: Diagnosis of Cystic Fibrosis
  • Exhibit 18: The Manifestations of Cystic Fibrosis
  • Exhibit 19: Snapshot of the Economic Burden of Cystic Fibrosis
  • Exhibit 20: Snapshot of Global Cystic Fibrosis Market 2014
  • Exhibit 21: Global Cystic Fibrosis Market 2014-2019 (US$ million)
  • Exhibit 22: Global Cystic Fibrosis Market Segmentation By Class of Drugs
  • Exhibit 23: Global Cystic Fibrosis Drugs Market Segmentation by Molecule Type 2014
  • Exhibit 24: Global Cystic Fibrosis Market Segmentation By Route Of Administration
  • Exhibit 25: Global Cystic Fibrosis Drugs Market Segmentation by Route of Administration 2014
  • Exhibit 26: Global Cystic Fibrosis Market Segmentation by Dosage Form
  • Exhibit 27: Global Cystic Fibrosis Drugs Market Segmentation by Dosage Form 2014
  • Exhibit 28: Global Cystic Fibrosis Market by Geographical Segmentation 2014 and 2019
  • Exhibit 29: Global Cystic Fibrosis Market Revenue by Geographical Segmentation 2014-2019 (US$ million)
  • Exhibit 30: Global Cystic Fibrosis Market Growth Rate by Region 2014-2019
  • Exhibit 31: Revenue (US$ million) and CAGR of Global Cystic Fibrosis Market by Geographical Segments 2014 and 2019
  • Exhibit 32: Global Cystic Fibrosis Market by Country/Region 2014
  • Exhibit 33: Global Cystic Fibrosis Market by Country/Region 2014 (US$ million)
  • Exhibit 34: Cystic Fibrosis Market in the Americas 2014-2019 (US$ million)
  • Exhibit 35: Cystic Fibrosis Market Revenue in the Americas 2014-2019
  • Exhibit 36: Cystic Fibrosis Market Growth Rate in the Americas 2014-2019
  • Exhibit 37: Cystic Fibrosis Market in the Americas by Region 2014 and 2019
  • Exhibit 38: Revenue (US$ million) and CAGR of Cystic Fibrosis Market in the Americas by Regions 2014 and 2019
  • Exhibit 39: Cystic Fibrosis Market in the US 2014-2019 (US$ million)
  • Exhibit 40: Cystic Fibrosis Market in the Latin America 2014-2019 (US$ million)
  • Exhibit 41: Cystic Fibrosis Market in Canada 2014-2019 (US$ million)
  • Exhibit 42: Cystic Fibrosis Market in EMEA 2014-2019 (US$ million)
  • Exhibit 43: Cystic Fibrosis Market in EMEA by Country/Region 2014
  • Exhibit 44: Cystic Fibrosis Market in APAC 2014-2019 (US$ million)
  • Exhibit 45: Buying Criteria of Global Cystic Fibrosis Market
  • Exhibit 46: Global Cystic Fibrosis Market Share Analysis 2014
  • Exhibit 47: Global Sales Comparison of Pulmozyme 2013 vs 2012 (US$ Million)
  • Exhibit 48: Quarterly Sales Comparison of Pulmozyme in the US 1994-2008 (US$ Million)
  • Exhibit 49: Quarterly Sales Comparison of Pulmozyme Sales to Collaborators 1997-2008 (US$ Million)
  • Exhibit 50: Quarterly Sales Comparison of Pulmozyme Total Sales 1994-2008 (US$ Million)
  • Exhibit 51: Total Global Sales Comparison of Pulmozyme 1994-2008 (US$ Million)
  • Exhibit 52: TOBI Podhaler
  • Exhibit 53: YoY Sales Comparison of TOBI and TOBI Podhaler 2006-2013 (US$ Million)
  • Exhibit 54: YoY Sales Comparison of Kalydeco 2012-2013 (US$ Million)
  • Exhibit 55: Actavis: Business Segmentation 2014
  • Exhibit 56: Actavis: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 57: Actavis : Sales by Geography (in US$ million)
  • Exhibit 67: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2013 and 2014
  • Exhibit 68: F. Hoffmann-La Roche Ltd.: Sales by Geography 2014 (Pharmaceuticals Division)
  • Exhibit 69: F. Hoffmann-La Roche Ltd.: Sales by Geography 2014 (Diagnostics Division)
  • Exhibit 63: Gilead Sciences: Business Segmentation by Revenue 2014
  • Exhibit 64: Gilead Sciences: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 65: Gilead Sciences: Sales by Geography 2014
  • Exhibit 18: Novartis AG: Business Segmentation
  • Exhibit 19: Novartis AG: Revenue by Business Segmentation 2014
  • Exhibit 20: Novartis AG: Revenue by Business Segmentation 2013 and 2014 (US$ million)
  • Exhibit 21: Novartis AG: Revenue by Geographical Segmentation 2014
  • Exhibit 63: Vertex Pharmaceuticals: Business Segmentation by Revenue 2014
  • Exhibit 64: Vertex Pharmaceuticals: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 65: Vertex Pharmaceuticals: Sales by Geography 2014
Back to Top